Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Yousif Matloub, Bruce C. Bostrom, Stephen P. Hunger, Linda C. Stork, Anne Angiolillo, Harland Sather, Mei La, Julie M. Gastier-Foster, Nyla A. Heerema, Scott Sailer, Patrick J. Buckley, Blythe Thomson, Catherine Cole, James B. Nachman, Gregory Reaman, Naomi Winick, William L. Carroll, Meenakshi Devidas, Paul S. Gaynon

Blood (2011) 118 (2): 243–251.

https://doi.org/10.1182/blood-2010-12-322909

Published: 2011

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Linda C. Stork, Yousif Matloub, Emmett Broxson, Mei La, Rochelle Yanofsky, Harland Sather, Ray Hutchinson, Nyla A. Heerema, April D. Sorrell, Margaret Masterson, Archie Bleyer, Paul S. Gaynon

Blood (2010) 115 (14): 2740–2748.

https://doi.org/10.1182/blood-2009-07-230656

Published: 2010

Journal Articles

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Yousif Matloub, MD, Bruce C. Bostrom, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Stephen P Hunger, MD, Harland Sather, PhD, Stephen Linda, William L. Carroll, MD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2009) 114 (22): 320.

https://doi.org/10.1182/blood.V114.22.320.320

Published: 2009

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031.

Blood (2008) 112 (11): 911.

https://doi.org/10.1182/blood.V112.11.911.911

Published: 2008

Journal Articles

Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.

Blood (2007) 110 (11): 4.

https://doi.org/10.1182/blood.V110.11.4.4

Published: 2007

Journal Articles

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia

James B. Nachman, Nyla A. Heerema, Harland Sather, Bruce Camitta, Erik Forestier, Christine J. Harrison, Nicole Dastugue, Martin Schrappe, Ching-Hon Pui, Giuseppe Basso, Lewis B. Silverman, Gritta E. Janka-Schaub

Blood (2007) 110 (4): 1112–1115.

https://doi.org/10.1182/blood-2006-07-038299

Published: 2007

Journal Articles

Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.

Kirk R. Schultz, MD, Alexander Aledo, MD, W. Paul Bowman, MD, William Slayton, MD, PhD, Harland Sather, PhD, Cheryl L. Willman, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Michael J. Borowitz, PhD, Naomi Winick, MD, Stephen P. Hunger, MD, PhD, William L. Carroll, MD, PhD

Blood (2006) 108 (11): 283.

https://doi.org/10.1182/blood.V108.11.283.283

Published: 2006

Journal Articles

Factors Influencing Survival after Relapse from Childhood ALL: A Children’s Oncology Group Study.

Kim Nguyen, Su-Chun Cheng, Ph.D, Elizabeth Raetz, M.D., Harland Sather, Ph.D, William L. Carroll, M.D., Naomi Winick, M.D., Stephen P. Hunger, M.D., Paul Gaynon, M.D., Mignon L. Loh, M.D.

Blood (2006) 108 (11): 1855.

https://doi.org/10.1182/blood.V108.11.1855.1855

Published: 2006

Journal Articles

Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.

Kelly W. Maloney, MD, Eric Larsen, MD, Leonard A. Mattano, MD, Alison Friedmann, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, Stephen Hunger, MD, Naomi Winick, MD, William L. Carroll, MD

Blood (2006) 108 (11): 1865.

https://doi.org/10.1182/blood.V108.11.1865.1865

Published: 2006

Journal Articles

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Yousif Matloub, MD, Anne Angiolillo, MD, Bruce Bostrom, MD, Stephen P. Hunger, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Naomi Winick, MD, Paul S. Gaynon, MD

Blood (2006) 108 (11): 146.

https://doi.org/10.1182/blood.V108.11.146.146

Published: 2006

Journal Articles

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Yousif Matloub, Susan Lindemulder, Paul S. Gaynon, Harland Sather, Mei La, Emmett Broxson, Rochelle Yanofsky, Raymond Hutchinson, Nyla A. Heerema, James Nachman, Marilyn Blake, Linda M. Wells, April D. Sorrell, Margaret Masterson, John F. Kelleher, Linda C. Stork

Blood (2006) 108 (4): 1165–1173.

https://doi.org/10.1182/blood-2005-12-011809

Published: 2006

Journal Articles

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

Joanne M. Hilden, Patricia A. Dinndorf, Sharon O. Meerbaum, Harland Sather, Doojduen Villaluna, Nyla A. Heerema, Ron McGlennen, Franklin O. Smith, William G. Woods, Wanda L. Salzer, Helen S. Johnstone, Zoann Dreyer, Gregory H. Reaman

Blood (2006) 108 (2): 441–451.

https://doi.org/10.1182/blood-2005-07-3011

Published: 2006

Journal Articles

CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group.

Joanne M. Hilden, MD, Patricia A. Dinndorf, MD, Sharon O. Meerbaum, Harland Sather, PhD, Doojduen Villaluna, PhD, Nyla A. Heerema, PhD, Ron McGlennen, MD, Franklin O. Smith, MD, William G. Woods, MD, Zoann Dryer, MD, Gregory H. Reaman, MD

Blood (2005) 106 (11): 7.

https://doi.org/10.1182/blood.V106.11.7.7

Published: 2005

Journal Articles

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Suman Malempati, MD, Paul S. Gaynon, MD, Harland Sather, PhD, Mei K. La, MS, Linda C. Stork, MD

Blood (2004) 104 (11): 520.

https://doi.org/10.1182/blood.V104.11.520.520

Published: 2004

Journal Articles

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Janet Franklin, MD, MPH, Staci Larsen, BA, Fred Dorey, PhD, Anna Butturini, MD, Cecelia Fu, MD, Beverly Lange, MD, Harland Sather, PhD, Paul Gaynon, MD

Blood (2004) 104 (11): 1958.

https://doi.org/10.1182/blood.V104.11.1958.1958

Published: 2004

Journal Articles

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Kirk R. Schultz, MD, Jeanette Pullen, MD, Harland Sather, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Paul S. Gaynon, MD, Bruce M. Camitta, MD

Blood (2004) 104 (11): 519.

https://doi.org/10.1182/blood.V104.11.519.519

Published: 2004

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

NARROW

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031.

Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia

Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.

Factors Influencing Survival after Relapse from Childhood ALL: A Children’s Oncology Group Study.

Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group.

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only